Korro Bio, Inc.
KRROKorro Bio is a biopharmaceutical company focused on developing a new class of genetic medicines through its proprietary OPERA platform, which utilizes RNA editing rather than DNA modification.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
Profile
Korro Bio is a biopharmaceutical company focused on developing a new class of genetic medicines through its proprietary OPERA platform, which utilizes RNA editing rather than DNA modification. The company's approach recruits endogenous ADAR enzymes via synthetic oligonucleotides to make precise single-nucleotide changes, aiming to treat both rare and highly prevalent diseases. Their core value proposition lies in providing transient, titratable, and redosable therapies that avoid the permanent off-target risks associated with traditional gene editing.
A pioneer in ADAR-mediated RNA editing utilizing a proprietary machine learning-driven platform (OPERA) to target the 'undruggable' proteome.
Questions, answered.
- What is Korro Bio, Inc.'s market cap?
- Korro Bio, Inc. (KRRO) has a market capitalization of $154.6M and trades on NASDAQ.
- Who are Korro Bio, Inc.'s competitors?
- Korro Bio, Inc.'s key competitors include Beam Therapeutics, Wave Life Sciences, ProQR Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Korro Bio, Inc. partner with?
- Korro Bio, Inc.'s notable partners include Novo Nordisk, Genevant Sciences.
- Where is Korro Bio, Inc. headquartered?
- Korro Bio, Inc. is headquartered in United States of America and employs approximately 101 people. It has been publicly traded since 2023.